MIZUHO MEDY CO.,LTD. (4595.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenJPY 1,734.00

From 52W high−9.81%

Volume48300.00

Market capJPY 33.09B

P/E (TTM)10.3x

P/S (TTM)3.1x

Div yield2.88%

Key dataSep 18, 2026

Open

JPY 1,734.00

From 52W high

−9.81%

Volume

48300.00

Market cap

JPY 33.09B

ValuationView details →

P/E (Fwd)

10.3x

EV/EBITDA

4.5x

P/E (TTM)

10.3x

RSI (14)

62.0

MomentumView details →

1D Return

+1.28%

YTD Return

+2.35%

ValuationView details →

P/E (Fwd)

10.3x

P/E (TTM)

10.3x

EV/EBITDA

4.5x

EV/Sales

1.9x

P/S (TTM)

3.1x

P/B (TTM)

1.8x

ProfitabilityView details →

Gross Margin

72.27%

Net Margin

30.03%

EBITDA Margin

45.40%

ROE (TTM)

17.72%

ROA (TTM)

15.52%

Asset Turnover

0.50x

GrowthView details →

Revenue YoY

−4.56%

EPS YoY

−9.25%

FCF YoY

—

Revenue CAGR 3Y

−13.80%

EPS CAGR 3Y

−39.77%

EBITDA YoY

—

MomentumView details →

1D Return

+1.28%

YTD Return

+2.35%

1Y Return

+9.27%

RSI (14)

62.0

vs 50D SMA

+2.89%

vs 200D SMA

+0.22%

Capital & dividendView details →

Debt/Equity

—

Current Ratio

11.59x

Quick Ratio

10.78x

Div Yield

2.88%

Div Rate

JPY 100.00

Div Growth 1Y

−50.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

10.82B

Net Income (TTM)

3.25B

Op. CF (TTM)

—

Next earningsNov 6, 2026 →

Latest newsMore news →

Mizuho Medy announced its financial results for the first half of fiscal year ending December 2026, with recurring profit down 20.5% year-on-year to 1.11 billion yen, and second-quarter (April-June) recurring profit down 13.5% to 280 million yen.40d ago

Mizuho Medy announced it will launch the Smart Gene Pertussis nucleic acid kit on August 3, 2026.66d ago

Similar companies

HEALIOS K.K.4593.T SEIKAGAKU CORPORATION4548.T Daito Pharmaceutical Co.,Ltd.4577.T Innovacell Inc.504A.T Fuji Pharma Co.,Ltd.4554.T Cuorips Inc.4894.T Find similar companies →

Latest newsMore news →

Mizuho Medy announced its financial results for the first half of fiscal year ending December 2026, with recurring profit down 20.5% year-on-year to 1.11 billion yen, and second-quarter (April-June) recurring profit down 13.5% to 280 million yen.40d ago Mizuho Medy announced it will launch the Smart Gene Pertussis nucleic acid kit on August 3, 2026.66d ago